Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 456, Issue 1, 2015, Pages 7-12

  Wang, Jingnan ^a   Hansen, Karyn ^b   Edwards, Robert ^b   Van Houten, Bennett ^c   Qian, Wei ^c  

^a Tsinghua University   (China)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bax Bak; Death ligands; Drp1; mdivi 1; Ovarian cancer; TRAIL

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; DEATH RECEPTOR; FAS LIGAND; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; 3-(2,4-DICHLORO-5-METHOXYPHENYL)-2-SULFANYL-4(3H)-QUINAZOLINONE; ANTINEOPLASTIC AGENT; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; DNM1L PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; LIGAND; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PROTEIN; QUINAZOLINONE DERIVATIVE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MODULATION; OVARY CANCER; PROTEIN FAMILY; CELL SURVIVAL; DRUG SCREENING; FIBROBLAST; GENE EXPRESSION REGULATION; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP PHOSPHOHYDROLASES; HUMANS; LIGANDS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL PROTEINS; OVARIAN NEOPLASMS; QUINAZOLINONES; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84919638437     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.11.010     Document Type: Article

References (27)

1. R.F. Ozols, M.A. Bookman, D.C. Connolly, M.B. Daly, A.K. Godwin, R.J. Schilder, X. Xu, and T.C. Hamilton Focus on epithelial ovarian cancer Cancer Cell 5 2004 19 24
2. L.K. Mullany, and J.S. Richards Minireview: animal models and mechanisms of ovarian cancer development Endocrinology 153 2012 1585 1592
3. T.J. Herzog Recurrent ovarian cancer: how important is it to treat to disease progression? Clin. Cancer Res. 10 2004 7439 7449
4. M.A. Bookman, M.F. Brady, W.P. McGuire, P.G. Harper, D.S. Alberts, M. Friedlander, N. Colombo, J.M. Fowler, P.A. Argenta, K. De Geest, D.G. Mutch, R.A. Burger, A.M. Swart, E.L. Trimble, C. Accario-Winslow, and L.M. Roth Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J. Clin. Oncol. 27 2009 1419 1425
5. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, R.S. Mannel, H.D. Homesley, J. Fowler, B.E. Greer, M. Boente, M.J. Birrer, and S.X. Liang Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 2011 2473 2483
6. S. Wang, and W.S. El-Deiry TRAIL and apoptosis induction by TNF-family death receptors Oncogene 22 2003 8628 8633
7. N.G. Khaider, D. Lane, I. Matte, C. Rancourt, and A. Piche Targeted ovarian cancer treatment: the TRAILs of resistance Am. J. Cancer Res. 2 2012 75 92
8. E.W. Duiker, E.G. de Vries, D. Mahalingam, G.J. Meersma, W. Boersma-van Ek, H. Hollema, M.N. Lub-de Hooge, G.M. van Dam, R.H. Cool, W.J. Quax, A. Samali, A.G. van der Zee, and S. de Jong Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model Clin. Cancer Res. 15 2009 2048 2057
9. S. Tomek, P. Horak, I. Pribill, G. Haller, M. Rossler, C.C. Zielinski, D. Pils, and M. Krainer Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs Gynecol. Oncol. 94 2004 107 114
10. S.J. Park, M.J. Kim, H.B. Kim, H.Y. Sohn, J.H. Bae, C.D. Kang, and S.H. Kim Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway Biochem. Pharmacol. 77 2009 1328 1336
11. J. Wang, J. Li, L. Santos, M. Shuda, R. Sobol, B. Van Houten, and W. Qian A novel strategy for targeted killing of tumor cells: induction of multipolar acentrosomal mitotic spindles with a quinazolinone derivative mdivi-1 Mol. Oncol. 2014 10.1016/j.molonc.2014.1010.1002 (in press)
12. W. Qian, J. Wang, V. Roginskaya, L.A. McDermott, R.P. Edwards, D.B. Stolz, F. Llambi, D.R. Green, and B. Van Houten Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells Oncotarget 5 2014 4180 4194
13. T.G. Shepherd, B.L. Theriault, E.J. Campbell, and M.W. Nachtigal Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients Nat. Protoc. 1 2006 2643 2649
14. N. Ishihara, M. Nomura, A. Jofuku, H. Kato, S.O. Suzuki, K. Masuda, H. Otera, Y. Nakanishi, I. Nonaka, Y. Goto, N. Taguchi, H. Morinaga, M. Maeda, R. Takayanagi, S. Yokota, and K. Mihara Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice Nat. Cell Biol. 11 2009 958 966
15. M.C. Wei, W.X. Zong, E.H. Cheng, T. Lindsten, V. Panoutsakopoulou, A.J. Ross, K.A. Roth, G.R. MacGregor, C.B. Thompson, and S.J. Korsmeyer Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 292 2001 727 730
16. M. Kessler, C. Fotopoulou, and T. Meyer The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin Int. J. Mol. Sci. 14 2013 6571 6596
17. E.W. Duiker, A. Meijer, A.R. van der Bilt, G.J. Meersma, N. Kooi, A.G. van der Zee, E.G. de Vries, and S. de Jong Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis Br. J. Cancer 104 2011 1278 1287
18. A. Cassidy-Stone, J.E. Chipuk, E. Ingerman, C. Song, C. Yoo, T. Kuwana, M.J. Kurth, J.T. Shaw, J.E. Hinshaw, D.R. Green, and J. Nunnari Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization Dev. Cell 14 2008 193 204
19. S. Wasiak, R. Zunino, and H.M. McBride Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death J. Cell Biol. 177 2007 439 450
20. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev. Cancer 3 2003 502 516
21. G.S. Wu TRAIL as a target in anti-cancer therapy Cancer Lett. 285 2009 1 5
22. D. Maksimovic-Ivanic, S. Stosic-Grujicic, F. Nicoletti, and S. Mijatovic Resistance to TRAIL and how to surmount it Immunol. Res. 52 2012 157 168
23. C.T. Hellwig, and M. Rehm TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies Mol. Cancer Ther. 11 2012 3 13
24. T.M. Ganten, T.L. Haas, J. Sykora, H. Stahl, M.R. Sprick, S.C. Fas, A. Krueger, M.A. Weigand, A. Grosse-Wilde, W. Stremmel, P.H. Krammer, and H. Walczak Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs Cell Death Differ. 11 Suppl. 1 2004 S86 96
25. M. Shigeno, K. Nakao, T. Ichikawa, K. Suzuki, A. Kawakami, S. Abiru, S. Miyazoe, Y. Nakagawa, H. Ishikawa, K. Hamasaki, K. Nakata, N. Ishii, and K. Eguchi Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation Oncogene 22 2003 1653 1662
26. L.L. Lackner, and J. Nunnari Small molecule inhibitors of mitochondrial division: tools that translate basic biological research into medicine Chem. Biol. 17 2010 578 583
27. K. Kandasamy, S.M. Srinivasula, E.S. Alnemri, C.B. Thompson, S.J. Korsmeyer, J.L. Bryant, and R.K. Srivastava Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release Cancer Res. 63 2003 1712 1721